EyePoint Pharmaceuticals Inc. buy JPMorgan Chase & Co.
Start price
22.01.24
/
50%
€21.60
Target price
22.01.25
€32.12
Performance (%)
-56.12%
Price
12.07.24
€9.48
Summary
This prediction is currently active. The BUY prediction by JPMorgan_Chase___Co_ for EyePoint Pharmaceuticals Inc. is performing very badly with a performance of -56.12%. This prediction currently runs until 22.01.25. The prediction end date can be changed by JPMorgan_Chase___Co_ at any time. JPMorgan_Chase___Co_ has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
EyePoint Pharmaceuticals Inc. | - | - |
iShares Core DAX® | 0.039% | 0.567% |
iShares Nasdaq 100 | -4.018% | -5.554% |
iShares Nikkei 225® | -2.389% | -1.434% |
iShares S&P 500 | -2.115% | -2.351% |
Comments by JPMorgan_Chase___Co_ for this prediction
In the thread EyePoint Pharmaceuticals Inc. diskutieren
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $35.00 price target on the stock.
Ratings data for EYPT provided by MarketBeat
Stopped prediction by JPMorgan_Chase___Co_ for EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€8.46
04.06.24
04.06.24
€29.43
04.06.25
04.06.25
12.09%
12.07.24
12.07.24